2,3-trimethylene-4-quinazolone has been researched along with Alzheimer Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Du, H; Ma, F | 1 |
| Du, H; Jiang, X; Liu, S; Ma, F; Ma, M; Xu, H | 1 |
| Jeripothula, M; Nerella, A | 1 |
| Ayyadevara, S; Balasubramaniam, M; Bowroju, SK; Crooks, PA; Lakkaniga, NR; Penthala, NR; Shmookler Reis, RJ | 1 |
| Emami, S; Haghighijoo, Z; Moosavi, F; Zamani, L | 1 |
| Gabr, MT; Hoda, N; Manzoor, S; Pal, K; Rasool, B | 1 |
| Du, H; Liu, X; Ma, F; Xie, J | 1 |
1 review(s) available for 2,3-trimethylene-4-quinazolone and Alzheimer Disease
| Article | Year |
|---|---|
Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Enzyme Inhibitors; Humans; Monoamine Oxidase; Neuroprotective Agents; Phosphoric Diester Hydrolases; Quinazolines; tau Proteins | 2022 |
6 other study(ies) available for 2,3-trimethylene-4-quinazolone and Alzheimer Disease
| Article | Year |
|---|---|
Novel deoxyvasicinone derivatives as potent multitarget-directed ligands for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Kinetics; Ligands; Molecular Structure; Peptide Fragments; Protein Aggregates; Quinazolines; Structure-Activity Relationship | 2017 |
Novel deoxyvasicinone and tetrahydro-beta-carboline hybrids as inhibitors of acetylcholinesterase and amyloid beta aggregation.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Carbolines; Cell Line; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological | 2020 |
Design, synthesis and biological evaluation of novel deoxyvasicinone-indole as multi-target agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Catalytic Domain; Cell Line, Tumor; Cholinesterase Inhibitors; Drug Design; Electrophorus; Horses; Indoles; Kinetics; Mice; Molecular Docking Simulation; Neuroprotective Agents; Peptide Fragments; Protein Binding; Protein Multimerization; Quinazolines; Rats | 2021 |
Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Animals; Benzylamines; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophorus; Horses; Humans; Molecular Structure; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Structure-Activity Relationship | 2021 |
Dual targeting of acetylcholinesterase and tau aggregation: Design, synthesis and evaluation of multifunctional deoxyvasicinone analogues for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Structure; Neuroprotective Agents; Protein Aggregates; Quinazolines; Structure-Activity Relationship; tau Proteins | 2021 |
Novel Deoxyvasicinone-Donepezil Hybrids as Potential Multitarget Drug Candidates for Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Cell Line; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Humans; In Vitro Techniques; Nootropic Agents; Quinazolines | 2019 |